各位股友，大家好，今日同大家睇吓「大市火車頭」港交所（00388）。以今日（1月30日）盤中數據嚟睇，情況有啲令人擔憂，截至下午兩點03分，股價最 新報430.2元，急跌超過3%，跑輸大市。成交額接近16億，算係有啲交投，但似乎係沽壓主導。成個大市氣氛轉弱，連帶呢隻市場寒暑表都受壓。你哋覺得 今次跌穿咗唔少平均線，係大戶散貨先兆，定只係一次健康調整，為下一輪升浪蓄力？ 技術走勢與關鍵位攻防 從圖表睇，港交所今日呢支陰燭幾關鍵，跌穿咗10天線（約430.16元）同30天線（約422.61元），暫時喺60天線（約418.91元）之上找到喘息空間。而家個 格局係，向下首要支持位要睇419元，如果連呢個位都失守，下一站就要試413元嘅較強支持區。至於向上，反彈第一個重型阻力喺445元，要收復返呢個位 先可以話脫離危險區，再上望就係452元。技術指標總結雖然話「買入」，但強度只有7。5日振幅有5.7%，反映波動性唔細。MACD同保力加通道卻發出 「買入」信號。其他指標如RSI喺57，威廉指標、隨機指標等都處於「中立」或「賣出」狀態。或者可以從波動中找到窩輪短炒契機。 窩輪與牛熊證機會風險並存 喺咁嘅波動市況，衍生工具可 ...

中國人壽（02628.HK）的股價在經歷前期顯著上漲後，進入一個關鍵的技術整固階段。市場正審視其短線回調壓力與長期行業復蘇邏輯之間的平衡。本文將整合最新 的技術指標、市場新聞動態以及【中銀做客】專欄的核心觀點，為投資者剖析其短期走勢，並提供在複雜市況下運用衍生工具的審慎策略。 一、技術分析：高位整固，關鍵支撐位面臨考驗 截止14點29分，股價報32.12元。從技術走勢觀察，中國人壽股價在創下近期高點後，但股價仍穩定運行於關鍵的30日移動平均線（約29.32元）及60日移動 平均線（約27.70元）之上，表明其中期上升趨勢結構尚未被破壞。然而，多個技術指標發出短期需要整固的信號。相對強弱指數（RSI）位於69，接近超買 區間，暗示短線買盤動能可能暫時消耗過大。此外，動量震盪指標發出了"賣出"信號，結合一目均衡表和MACD指標雖然維持"買入"指向但強度可能減弱的 情況，共同印證了股價在挑戰更高阻力前，於當前高位消化獲利盤的必要性。 當前市場對中國人壽的看法呈現出"長期趨勢向好"與"短期業績驗證"並存的格局，這與保險業整體的發展態勢緊密相連。 積極的長期趨勢與基本面改善。 在1月13日的【中銀做客】欄目中，中銀國際 ...

Core Viewpoint - The stock price of Kangfang Biotech (09926) is currently at 121 HKD, reflecting a 3.6% increase, with significant market activity and divergent views among investors [1][5]. Market Performance - Over the past five days, the stock has shown a volatility of 11.9%, with a trading volume of 236 million HKD, indicating active trading [1]. - Other stocks in the same sector have varied performances, with BeiGene (06160.HK) up 0.95% at 191.5 HKD, Innovent Biologics (01801.HK) up 0.24% at 83.75 HKD, and others showing declines [1]. Technical Analysis - The current stock price is slightly below the 10-day moving average (121.5 HKD) but above the 30-day moving average (116.85 HKD), indicating short-term pressure while the mid-term structure remains intact [2]. - Key support levels are identified at 111.7 HKD (Support 1) and 103.3 HKD (Support 2), with resistance levels at 123 HKD (Resistance 1) and 130.3 HKD (Resistance 2) [2]. - The overall probability of an upward movement is estimated at 56%, suggesting a slightly positive outlook [2]. Fundamental Catalysts - A significant recent development is the inclusion of all five self-developed drugs by Kangfang Biotech in the latest National Medical Insurance catalog, effective January 1, 2026 [5]. - This inclusion is viewed as a critical step towards accelerating the commercialization of innovative drugs, with expectations of rapid sales growth following the listing [5]. Investor Sentiment - Investor opinions are divided into three main perspectives: 1. Optimistic view anticipating significant stock price increases due to potential market expansion from medical insurance [5]. 2. Cautious view considering previous price volatility, leading some investors to take profits at current levels [5]. 3. Pessimistic view predicting a potential price correction to around 110 HKD for consolidation [5]. Derivative Products - In a volatile market, the leverage characteristics of derivative products are highlighted, with examples showing significant price movements in response to stock fluctuations [6][7]. - For bullish investors, options such as Huatai call warrants (22043) with a strike price of 138 HKD and a leverage of 2.7 times are recommended [9]. - For bearish investors, Huatai put warrants (29749) with a strike price of 95 HKD and a leverage of 1.2 times are suggested for hedging against potential declines [16].

Group 1 - WuXi Biologics announced the successful completion of pilot-scale end-to-end automated continuous production using its high-efficiency continuous perfusion production technology platform WuXiUP, which will be further promoted in major GMP production bases to enhance efficiency and flexibility in accelerating the entire process from R&D to commercialization of biopharmaceuticals [1] Group 2 - As of August 14, 2025, WuXi Biologics' stock price reached 30.7 HKD, successfully surpassing the 10-day moving average of 30.69 HKD and breaking through the 30-day moving average of 29.25 HKD, indicating a strengthening short-term technical trend [2] - The stock is currently challenging an important resistance level at 33.8 HKD, and if it breaks through, it will open up further upward potential [2][6] Group 3 - Technical indicators show a "buy" signal for WuXi Biologics, with a strength index of 10, and the MACD indicator maintaining a buy signal, indicating a positive medium-term trend [3] - The RSI indicator is at 62, in a neutral to strong zone, suggesting further upward potential, while the CCI indicator is in a neutral zone [3] Group 4 - Recent performance of derivative products related to WuXi Biologics has been impressive, with Societe Generale's bull certificate recording a 43% increase when the underlying stock rose by 6.16%, showcasing the explosive potential of bull certificates in trending markets [7] - HSBC's bull certificate also performed well, increasing by 41% [7] Group 5 - For investors optimistic about the market, HSBC's call option 14447 offers a leverage of 2.2 times with an exercise price of 29.15 HKD, which can effectively reduce holding costs [10] - UBS's call option 15586 is also noteworthy, suitable for investors expecting a breakout [10] Group 6 - The current stock price is facing critical technical levels, with support at 29.1 HKD and stronger support at 27.3 HKD, while the upper resistance is at 33.8 HKD, which is a psychological barrier [6] - If the stock can effectively break through this resistance, it will challenge a higher target of 35.5 HKD [6]